Health Catalyst Inc

HCAT is in a Stage 2 advance with clear higher highs and higher lows and rising short-term EMAs, but price is extended above EMAs and overbought in the short term. Medium-term bias remains bullish after the recent breakout, yet execution should wait for a pullback into the rising 9/20 EMA zone or the lower portion of the breakout range before participation.

• ↑Q1 revenue of $70.8M exceeded management guidance
• ↑Adjusted EBITDA of $9.1M with 51.5% gross margin
• ↓Q1 revenue fell 11% YoY; net loss driven by $111M impairment